Search

Your search keyword '"Heijmen, Ben J.M."' showing total 220 results
Start Over Author "Heijmen, Ben J.M."
220 results on '"Heijmen, Ben J.M."'

4. The Dutch–Belgian Registry of Stereotactic Body Radiation Therapy for Liver Metastases: Clinical Outcomes of 515 Patients and 668 Metastases

Author

Méndez Romero, Alejandra, Schillemans, Wilco, van Os, Rob, Koppe, Friederike, Haasbeek, Cornelis J., Hendriksen, Ellen M., Muller, Karin, Ceha, Heleen M., Braam, Pètra M., Reerink, Onne, Intven, Martijn P.M., Joye, Ines, Jansen, Edwin P.M., Westerveld, Henrike, Koedijk, Merel S., Heijmen, Ben J.M., and Buijsen, Jeroen

Published
2021
Full Text
View/download PDF

5. Transarterial Chemoembolization With Drug-Eluting Beads Versus Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma: Outcomes From a Multicenter, Randomized, Phase 2 Trial (the TRENDY Trial)

Author

Méndez Romero, Alejandra, primary, van der Holt, Bronno, additional, Willemssen, Francois E.J.A., additional, de Man, Rob A., additional, Heijmen, Ben J.M., additional, Habraken, Steven, additional, Westerveld, Henrike, additional, van Delden, Otto M., additional, Klümpen, Heinz-Josef, additional, Tjwa, Eric T.T.L., additional, Braam, Pètra M., additional, Jenniskens, Sjoerd F.M., additional, Vanwolleghem, Thomas, additional, Weytjens, Reinhilde, additional, d'Archambeau, Olivier, additional, de Vos-Geelen, Judith, additional, Buijsen, Jeroen, additional, van der Leij, Christiaan, additional, den Toom, Wilhelm, additional, Sprengers, Dave, additional, IJzermans, Jan N.M., additional, and Moelker, Adriaan, additional

Published
2023
Full Text
View/download PDF

10. The TRENDY multi-center randomized trial on hepatocellular carcinoma – Trial QA including automated treatment planning and benchmark-case results

Author

Habraken, Steven J.M., Sharfo, Abdul Wahab M., Buijsen, Jeroen, Verbakel, Wilko F.A.R., Haasbeek, Cornelis J.A., Öllers, Michel C., Westerveld, Henrike, van Wieringen, Niek, Reerink, Onne, Seravalli, Enrica, Braam, Pètra M., Wendling, Markus, Lacornerie, Thomas, Mirabel, Xavier, Weytjens, Reinhilde, Depuydt, Lieselotte, Tanadini-Lang, Stephanie, Riesterer, Oliver, Haustermans, Karin, Depuydt, Tom, Dwarkasing, Roy S., Willemssen, François E.J.A., Heijmen, Ben J.M., and Méndez Romero, Alejandra

Published
2017
Full Text
View/download PDF

15. TACE-DEB vs. SBRT for hepatocellular carcinoma

Author

Romero, Alejandra Méndez, van der Holt, Bronno, Willemssen, Francois E.J.A., de Man, Rob A., Heijmen, Ben J.M., Habraken, Steven, Westerveld, Henrike, van Delden, Otto M., Klümpen, Heinz-Josef, Tjwa, Eric T.T.L., Braam, Pètra M., Jenniskens, Sjoerd F.M, Vanwolleghem, Thomas, Weytjens, Reinhilde, d'Archambeau, Olivier, de Vos-Geelen, Judith, Buijsen, Jeroen, van der Leij, Christiaan, den Toom, Wilhelm, Sprengers, Dave, Ijzermans, Jan N.M., and Moelker, Adriaan

Subjects
Human medicine
Abstract

Purpose To compare transarterial chemoembolization delivered with drug eluting beads (TACE-DEB) with stereotactioc body radiation therapy (SBRT) in patients with hepatocellular carcinoma (HCC) in a multicenter randomized trial. Materials and Methods Patients were included if they were eligible for TACE. They could also be recruited if they required treatment prior to liver transplantation. A maximum of four TACE-DEB procedures and ablation after incomplete TACE-DEB were both allowed. SBRT was delivered in six fractions of 8-9Gy. Primary end point was time to progression (TTP). Secondary endpoints were local control (LC), overall survival (OS), response rate (RR), toxicity, and quality of life (QoL). The calculated sample size was 100 patients. Results Between May 2015 and April 2020, 30 patients were randomized to the study. Due to slow accrual the trial was closed prematurely. Two patients in the SBRT arm were considered ineligible leaving 16 patients in the TACE-DEB arm and 12 in the SBRT arm. Median follow-up was 28.1 months. Median TTP was 12 months for TACE-DEB and 19 months for SBRT (p=0.15). Median LC was 12 months for TACE-DEB and >40 months (not reached) for SBRT (p=0.075). Median OS was 36.8 months for TACE-DEB and 44.1 months for SBRT (p=0.36). A post-hoc analysis showed 100% for SBRT 1- and 2-year LC, and 54.4% and 43.6% for TACE-DEB (p=0.019). Both treatments resulted in RR>80%. Three episodes of possibly related toxicity grade ≥3 were observed after TACE-DEB. No episodes were observed after SBRT. QoL remained stable after both treatment arms. Conclusions In this trial, TTP after TACE-DEB was not significantly improved by SBRT, while SBRT showed higher local antitumoral activity than TACE-DEB, without detrimental effects on OS, toxicity and QoL. To overcome poor accrual in randomized trials that include SBRT, and to generate evidence for including SBRT in treatment guidelines, international cooperation is needed.

Published
2023

20. Patient selection, inter-fraction plan robustness and reduction of toxicity risk with deep inspiration breath hold in intensity-modulated radiotherapy of locally advanced non-small cell lung cancer

Author

Fjellanger, Kristine, Rossi, Linda, Heijmen, Ben J.M., Pettersen, Helge Egil Seime, Sandvik, Inger Marie, Breedveld, Sebastiaan, Sulen, Turid Husevåg, Hysing, Liv Bolstad, and Radiation Oncology

Subjects
Cancer Research, Oncology, SDG 3 - Good Health and Well-being
Abstract

BackgroundState-of-the-art radiotherapy of locally advanced non-small cell lung cancer (LA-NSCLC) is performed with intensity-modulation during free breathing (FB). Previous studies have found encouraging geometric reproducibility and patient compliance of deep inspiration breath hold (DIBH) radiotherapy for LA-NSCLC patients. However, dosimetric comparisons of DIBH with FB are sparse, and DIBH is not routinely used for this patient group. The objective of this simulation study was therefore to compare DIBH and FB in a prospective cohort of LA-NSCLC patients treated with intensity-modulated radiotherapy (IMRT).MethodsFor 38 LA-NSCLC patients, 4DCTs and DIBH CTs were acquired for treatment planning and during the first and third week of radiotherapy treatment. Using automated planning, one FB and one DIBH IMRT plan were generated for each patient. FB and DIBH was compared in terms of dosimetric parameters and NTCP. The treatment plans were recalculated on the repeat CTs to evaluate robustness. Correlations between ΔNTCPs and patient characteristics that could potentially predict the benefit of DIBH were explored.ResultsDIBH reduced the median Dmean to the lungs and heart by 1.4 Gy and 1.1 Gy, respectively. This translated into reductions in NTCP for radiation pneumonitis grade ≥2 from 20.3% to 18.3%, and for 2-year mortality from 51.4% to 50.3%. The organ at risk sparing with DIBH remained significant in week 1 and week 3 of treatment, and the robustness of the target coverage was similar for FB and DIBH. While the risk of radiation pneumonitis was consistently reduced with DIBH regardless of patient characteristics, the ability to reduce the risk of 2-year mortality was evident among patients with upper and left lower lobe tumors but not right lower lobe tumors.ConclusionCompared to FB, DIBH allowed for smaller target volumes and similar target coverage. DIBH reduced the lung and heart dose, as well as the risk of radiation pneumonitis and 2-year mortality, for 92% and 74% of LA-NSCLC patients, respectively. However, the advantages varied considerably between patients, and the ability to reduce the risk of 2-year mortality was dependent on tumor location. Evaluation of repeat CTs showed similar robustness of the dose distributions with each technique.

Published
2022

Catalog

Books, media, physical & digital resources
See catalog results